Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
meropenem trihydrate, Quantity: 1141 mg (Equivalent: meropenem, Qty 1000 mg)
Arrotex Pharmaceuticals Pty Ltd
Meropenem trihydrate
Injection, powder for
Excipient Ingredients: sodium carbonate
Intravenous
10 vials
(S4) Prescription Only Medicine
Meropenem is indicated for treatment of the following infections, in adults and children (aged 3 months and over), when the causative organisms are known or suspected to be resistant to commonly used antibiotics: Community acquired lower respiratory tract infection; Hospital acquired lower respiratory tract infection; Complicated urinary tract infection; Febrile neutropenia; Intra-abdominal and gynaecological (poly microbial) infections; Complicated skin and skin structure infections; Meningitis; Septicaemia
Visual Identification: White to slightly yellow powder; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 36 Months; Container Temperature: Store below 30 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert
Licence status A
2014-12-18